This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duda, D. G. Articles by Willett, C. G. Search for Related Content PubMed PubMed Citation Articles by Duda, D. G. Articles by Willett, C. G.

Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers

Dan G. Duda, Rakesh K. Jain, Christopher G. Willett

From the Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA; and the Department of Radiation Oncology, Duke University Medical Center, Durham, NC

Address reprint requests to Christopher G. Willett, MD, Box 3085, Duke University Medical Center, Durham, NC 27710; e-mail: christopher.willett{at}duke.edu or Dan G. Duda, DMD, PhD, Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom St, Cox-734, Boston, MA 02114; e-mail: duda{at}steele.mgh.harvard.edu

Although still in very early stages of clinical development, the combination of antiangiogenics with contemporary chemoradiotherapy regimens has emerged as a feasible and promising approach to many cancers. We review the rationale and the current understanding of antiangiogenics and their therapeutic potential in combination with chemoradiotherapy. Finally, we offer a perspective on future research directions aimed at making this complex therapeutic approach successful in the clinic.

Supported by National Cancer Institute Grants No. R21 CA099237 (to C.G.W.) and P01 CA80124 and R01 CA115767 (to R.K.J.), a National Foundation for Cancer Research Grant (to R.K.J.) and an American Association for Cancer Research–Genentech BioOncology Career Development Award (to D.G.D.).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article

This article has been cited by other articles:

				S. P. Dineen, K. D. Lynn, S. E. Holloway, A. F. Miller, J. P. Sullivan, D. S. Shames, A. W. Beck, C. C. Barnett, J. B. Fleming, and R. A. Brekken Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice Cancer Res., June 1, 2008; 68(11): 4340 - 4346. [Abstract] [Full Text] [PDF]

				N. A.J.B. Peters, D. J. Richel, J. J.C. Verhoeff, and L. J.A. Stalpers Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib J. Clin. Oncol., May 10, 2008; 26(14): 2405 - 2406. [Full Text] [PDF]